Stem Cell Treatment for Cerebral Palsy

Stem Cell Treatment for Cerebral Palsy

Stem Cell Treatments for Cerebral Palsy are Currently Available at SIRM

Because Cerebral Palsy is a condition that encompasses a group of non-progressive, non-contagious motor conditions that cause physical disability in human development, we aim to treat it with Stem Cell Therapy.

Cerebral refers to the cerebrum, which is the affected area of the brain (although the disorder most likely involves connections between the cortex and other parts of the brain such as the cerebellum), and palsy refers to disorder of movement. Cerebral palsy is caused by damage to the motor control centers of the developing brain and can occur during pregnancy, during childbirth or after birth up to about age three. Resulting limits in movement and posture cause activity limitation and are often accompanied by disturbances of sensation, depth perception and other sight-based perceptual problems, communication ability; impairments can also be found in cognition, and epilepsy is found in about one-third of cases. CP, no matter what the type, is often accompanied by secondary musculoskeletal problems that arise as a result of the underlying etiology.

Cerebral Palsy Stem Cell Treatment

Asphyxia, Infections, and Inflammation during Intrauterine development seemed to be the causes.

There are 4 types:

  1. Spastic - 80% and most common; hypertonic and have what is essentially a neuromuscular mobility impairment (rather than hypotonia or paralysis) stemming from an upper motor neuron lesion in the brain as well as the corticospinal tract or the motor cortex. This damage impairs the ability of some nerve receptors in the spine to properly receive gamma amino butyric acid, leading to hypertonia in the muscles signaled by those damaged nerves.
  2. Ataxic - caused by damage to the cerebellum, and it is common for individuals to have difficulty with visual and/or auditory processing.
  3. Dyskinetic - is mixed muscle tone – both hypertonia and hypotonia mixed with involuntary motions. People with Dyskinetic CP have trouble holding themselves in an upright, steady position for sitting or walking, and often show involuntary motions.
  4. Mixed - A combination of the above

Cerebral Palsy Stem Cell Treatment and stem cell therapy. Cerebral Palsy treatment studies and stem cell protocols:

Related Articles Outcomes of autologous bone marrow mononuclear cells for cerebral palsy: an open label uncontrolled clinical trial. BMC Pediatr. 2017 Apr 12;17(1):104 Authors: Nguyen LT, Nguyen AT, Vu CD, Ngo DV, Bui AV Abstract BACKGROUND: Stem cell therapy has emerged as a promising method for improving motor function of patients with cerebral palsy. The aim of this study is to assess the safety and effectiveness of autologous bone marrow mononuclear stem cell transplantation in patients with cerebral palsy related to oxygen deprivation. METHODS: An open label uncontrolled clinical trial was carried out at Vinmec International Hospital. The intervention consisted of two administrations of stem cells, the first at baseline and the second 3 months later. Improvement was monitored at 3 months and 6 months after the first administration of stem cells, using the Gross Motor Function Measure (GMFM) and Modified Ashworth Score which measures muscle tone. RESULTS: No severe complications were recorded during the study. After transplantation, 12 patients encountered fever without infections and 9 patients experienced vomiting which was easily managed with medications. Gross motor function was markedly improved 3 months or 6 months after stem cell transplantation than at baseline. The post-transplantation GMFM-88 total score, each of its domains and the GMFM-66 percentile were all significantly higher (p-value < 0.001). Muscle spasticity also reduced significantly after transplantation (p-value < 0.001). The therapy was equally effective regardless of sex, age and GMFCS level (p-value > 0.05). CONCLUSION: Autologous bone marrow mononuclear cell transplantation appears to be a safe and effective therapy for patients with cerebral palsy. TRIAL REGISTRATION: Identifier: NCT02569775 . Retrospectively registered on October 15, 2015. PMID: 28403842 [PubMed - in process]

Quick Contact Form